Bluebird bio (BLUE), Carlyle (CG), SK Capital Partners and Beacon Parent said late Monday that all required regulatory approvals have been received for the Bluebird bio's acquisition by Carlyle and SK Capital.
The companies said no additional approvals are needed, and the merger is expected to close soon on May 12.
Under the deal, Bluebird bio's shareholders will receive $3 per share in cash upfront and a contingent value right worth up to $6.84 per share, based on future sales milestones, bringing the total potential value to $9.84 per share.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。